Abstract
Glioma is still one of the most aggressive forms of brain tumors. Understanding of the biological and pathophysiological mechanisms of survival can help the researchers to develop new management modalities. Industrial toxins could be one of the most important causes for brain tumors, such as dioxin and other aryl hydrocarbon receptor (AhR) ligands. Toxicity of these compounds includes a series of cellular events starting from binding with AhR and ending with the increased expression of a group of xenobiotic metabolizing enzymes (XME) such as the cytochrome P450 (CYPs), CYP1A1, CYP1A2, and CYP1B1. Therefore, identification of the localizations and expressions of the AhR and its regulated CYPs in the central nervous system (CNS) and neuronal cells is of major importance in understanding their physiological and pathological roles. Generally, low but significant level of CYPs expression is demonstrated in the brain in a tissue- and species-specific manner. Moreover, most, but not all, AhR-regulated CYPs are expressed differently in most of the neuronal and glial cells. Although the exact mechanisms of AhR-mediated glioma and neurotoxicity are not fully understood, the present review proposes several mechanisms which include generating reactive oxygen species, activating glutamate receptors, peroxisome proliferator- activated receptors, histone acetylation, and signal transducer and activator of transcription 3.
Keywords: Glioma, Aryl hydrocarbon receptor, CYP1A1, CYP1B1, Glutamate receptor, Histone acetylation, STAT3, and PPAR.
Current Pharmaceutical Design
Title:The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Volume: 19 Issue: 40
Author(s): Hesham M. Korashy, Hatim M. Abuohashish and Zaid H. Maayah
Affiliation:
Keywords: Glioma, Aryl hydrocarbon receptor, CYP1A1, CYP1B1, Glutamate receptor, Histone acetylation, STAT3, and PPAR.
Abstract: Glioma is still one of the most aggressive forms of brain tumors. Understanding of the biological and pathophysiological mechanisms of survival can help the researchers to develop new management modalities. Industrial toxins could be one of the most important causes for brain tumors, such as dioxin and other aryl hydrocarbon receptor (AhR) ligands. Toxicity of these compounds includes a series of cellular events starting from binding with AhR and ending with the increased expression of a group of xenobiotic metabolizing enzymes (XME) such as the cytochrome P450 (CYPs), CYP1A1, CYP1A2, and CYP1B1. Therefore, identification of the localizations and expressions of the AhR and its regulated CYPs in the central nervous system (CNS) and neuronal cells is of major importance in understanding their physiological and pathological roles. Generally, low but significant level of CYPs expression is demonstrated in the brain in a tissue- and species-specific manner. Moreover, most, but not all, AhR-regulated CYPs are expressed differently in most of the neuronal and glial cells. Although the exact mechanisms of AhR-mediated glioma and neurotoxicity are not fully understood, the present review proposes several mechanisms which include generating reactive oxygen species, activating glutamate receptors, peroxisome proliferator- activated receptors, histone acetylation, and signal transducer and activator of transcription 3.
Export Options
About this article
Cite this article as:
Korashy M. Hesham, Abuohashish M. Hatim and Maayah H. Zaid, The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/13816128113199990583
DOI https://dx.doi.org/10.2174/13816128113199990583 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Recent Trends of Biocompatible and Biodegradable Nanoparticles in Drug Delivery: A Review
Current Medicinal Chemistry MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Transfer of Biologically Important Molecules Between Cells Through Gap Junction Channels
Current Medicinal Chemistry A Mini Review on Interactions Between Neural Stem Cells and Biomaterials
Recent Patents on Regenerative Medicine Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics